Key Takeaways
- Simultaneous intravitreal dexamethasone and aflibercept led to sustained improvements in visual acuity and central retinal thickness over 24 months in eyes with DME.
- Significant anatomical and visual gains were observed as early as 6 months and maintained through 2 years of follow-up.
- Patients required an average of just over three treatments across the study period, with retreatment intervals of approximately 10 months.
Patients with diabetic macular edema (DME) treated with simultaneous intravitreal dexamethasone and aflibercept experienced sustained improvements in both visual acuity and retinal thickness over a 24-month follow-up period, with relatively infrequent retreatment, according to a study.
The multicenter retrospective study initially included 76 eyes, with 52 eyes having available data at 24 months. Compared with baseline, mean best-corrected visual acuity and central retinal thickness showed significant improvements at 6, 12, 18, and 24 months. Over the study period, patients received an average of 3.26 ± 1.70 intravitreal treatments, with a mean retreatment interval of 10.21 ± 6.35 months.
According to the investigators, simultaneous treatment with intravitreal dexamethasone and aflibercept was associated with sustained visual and anatomical improvements over 24 months in eyes with DME.
Reference
Lin TC, Huang HW, Chung YC, Hsu TK, Huang YM, Chi SC, Chao CY, Tseng PC. Two-year treatment outcomes of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema. Ophthalmologica. 2026;1-21. doi: 10.1159/000550320. Epub ahead of print. PMID: 41490022.
Related Content
